

# Coloplast – transactions in connection with share buy-back programme, week 16 (programme completed)

As mentioned in Announcement no. 03/2022 Coloplast has initiated a share buyback programme totalling up to DKK 500 million.

The share buyback programme was carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

The following transactions have been executed during the period 18 - 22 April 2022:

Date	Number of shares	Average purchase price, DKK	Transaction value, DKK
18 April 2022	-	-	-
19 April 2022	10,830	1,053.05	11,404,500
20 April 2022	592	1,068.61	632,616
21 April 2022	15,316	1,060.22	16,238,368
22 April 2022	-	-	-
Accumulated until now under the programme	512,760	975.11	499,999,310

Henceforth, Coloplast owns 3,692,876 treasury B shares of DKK 1 equal to 1,71% of the company's total share capital.

An overview showing the transaction data for the period 18 - 22 April 2022 is enclosed.

Coloplast's share buyback programme initiated on 21 February 2022, and as described in Announcement 03/2022, is hereby completed.

Kind regards, Investor Relations Coloplast A/S Tel. +45 4911 1800 Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Tel: +45 4911 1111 www.coloplast.com Company reg. (CVR) no. 69749917



## Our mission

Making life easier for people with intimate healthcare needs

#### Our values

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

### **Our vision**

Setting the global standard for listening and responding

# For further information, please contact

# **Investors and analysts**

Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111

Ellen Bjurgert Vice President, Investor Relations Tel. +45 4911 1800 /+45 4911 3376 Email: dkebj@coloplast.com

Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 /+45 4911 2458 Email: dkadim@coloplast.com

# Press and the media

Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: dkpete@coloplast.com

## **Address**

Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917

# Website

www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound & Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ about 14,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2022-04. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.